Maria L. Musumeci
Santa Sofia Street 78
Catania, 95100, Italy
Catania, 95100, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 110 publications
Clinical profile, patient experience, and management of vitiligo in Italy: Data from the National 2024 Vitiligo Week Awareness Campaign.
Journal: JAAD international
Published: August 01, 2026
Screening for Eating Disorders in Psoriasis Patients: A Multicenter Cross-Sectional Study.
Journal: Psoriasis (Auckland, N.Z.)
Published: July 08, 2026
Recurrent antibiotic burden during adalimumab therapy in hidradenitis suppurativa.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: May 25, 2026
Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.
Journal: The British journal of dermatology
Published: May 16, 2026
Real-Life Effectiveness, Safety, and Growth Outcomes of Dupilumab in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Study from an Italian NPP Program.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: May 07, 2026
Psoriatic patients with cancer: a multicentric real-life study comparing Risankizumab and Apremilast.
Journal: Dermatology (Basel, Switzerland)
Published: March 04, 2026
Line-field Confocal Optical Coherence Tomography Detects Subclinical Disease Activity in Atopic Dermatitis during Treatment with Pimecrolimus: An Intrapatient, Controlled Study.
Journal: Acta dermato-venereologica
Published: February 03, 2026
Reevaluating red nodules in hidradenitis suppurativa: clinical, dermatoscopic and histopathologic correlation.
Journal: Italian journal of dermatology and venereology
Published: January 12, 2026
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis).
Journal: Acta dermato-venereologica
Published: November 16, 2025
Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study.
Journal: Clinical and experimental dermatology
Published: October 21, 2025
Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study.
Journal: Clinical and experimental dermatology
Published: July 01, 2025
Letter: Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting-IL AD.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: June 05, 2025
Last Updated: 09/26/2026